TY - THES A1 - Vogel, Heike T1 - Genetics of obesity and type 2 diabetes N2 - By using mouse outcross populations in combination with bioinformatic approaches, it was possible to identify and characterize novel genes regulating body weight, fat mass and β-cell function, which all contribute to the pathogenesis of obesity and T2D. In detail, the presented studies identified 1. Ifi202b/IFI16 as adipogenic gene involved in adipocyte commitment, maintenance of white adipocyte identity, fat cell size and the inflammatory state of adipose tissue. 2. Pla2g4a/PLA2G4A as gene linked to increased body weight and fat mass with a higher expression in adipose tissue of obese mice and pigs as well as in obese human subjects. 3. Ifgga2/IRGM as novel regulator of lipophagy protecting from excess hepatic lipid accumulation. 4. Nidd/DBA as a diabetogenic locus containing Kti12, Osbpl9, Ttc39a and Calr4 with differential expression in pancreatic islets and/or genetic variants. 5. miR-31 to be higher expressed in adipose tissue of obese and diabetic mice and humans targeting PPARy and GLUT4 and thereby involved in adipogenesis and insulin signaling. 6. Gjb4 as novel gene triggering the development of T2D by reducing insulin secretion, inducing apoptosis and inhibiting proliferation. The performed studies confirmed the complexity and strong genetic heritability character of obesity and T2D. A high number of genetic variations, each with a small effect, are collectively influencing the degree and severity of the disease. The use of mouse outcross populations is a valid tool for disease gene identification; however, to facilitate and accelerate the process of gene identification the combination of mouse cross data with advanced sequencing resources and the publicly available data sets are essential. The main goal for future studies should be the translation of these novel molecular discoveries to useful treatment therapies. More recently, several classes of novel unimolecular combination therapeutics have emerged with superior efficacy than currently prescribed options and pose the potential to reverse obesity and T2D (Finan et al., 2015). The glucagon-like peptide-1 (GLP-1)- estrogen conjugate, which targets estrogen into cells expressing GLP-1 receptors, was shown to improve energy, glucose and lipid metabolism as well as to reduce food reward (Finan et al., 2012; Schwenk et al., 2014; Vogel et al., 2016). Another possibility is the development of miRNA-based therapeutics to prevent obesity and T2D, such as miRNA mimetics, anti-miRNA oligonucleotides and exosomes loaded with miRNAs (Ji and Guo, 2019; Gottmann et al., 2020). As already described, genome-wide association studies for polygenic obesity and T2D traits in humans have also led to the identification of numerous gene variants with modest effect, most of them having an unknown function (Yazdi et al., 2015). These discoveries resulted in novel animal models and have illuminated new biologic pathways. Therefore, the integration of mouse-human genetic approaches and the utilization of the synergistic effects have the potential to lead to the identification of more genes responsible for common Mendelian forms of obesity and T2D, as well as gene × gene and gene × environment interactions (Yazdi et al., 2015; Ingelsson and McCarthy, 2018). This combination may help to unravel the missing heritability of obesity and T2D, to identify novel drug targets and to design more efficient and personalized obesity prevention and management programs. Y1 - 2021 CY - Potsdam ER - TY - THES A1 - Laeger, Thomas T1 - Protein-dependent regulation of feeding, metabolism, and development of type 2 diabetes T1 - Proteinabhängige Regulation der Nahrungsaufnahme und des Metabolismus sowie Entstehung des Typ-2-Diabetes BT - FGF21’s biological role BT - die Rolle von FGF21 N2 - Food intake is driven by the need for energy but also by the demand for essential nutrients such as protein. Whereas it was well known how diets high in protein mediate satiety, it remained unclear how diets low in protein induce appetite. Therefore, this thesis aims to contribute to the research area of the detection of restricted dietary protein and adaptive responses. This thesis provides clear evidence that the liver-derived hormone fibroblast growth factor 21 (FGF21) is an endocrine signal of a dietary protein restriction, with the cellular amino acid sensor general control nonderepressible 2 (GCN2) kinase acting as an upstream regulator of FGF21 during protein restriction. In the brain, FGF21 is mediating the protein-restricted metabolic responses, e.g. increased energy expenditure, food intake, insulin sensitivity, and improved glucose homeostasis. Furthermore, endogenous FGF21 induced by dietary protein or methionine restriction is preventing the onset of type 2 diabetes in the New Zealand Obese mouse. Overall, FGF21 plays an important role in the detection of protein restriction and macronutrient imbalance in rodents and humans, and mediates both the behavioral and metabolic responses to dietary protein restriction. This makes FGF21 a critical physiological signal of dietary protein restriction, highlighting the important but often overlooked impact of dietary protein on metabolism and eating behavior, independent of dietary energy content. N2 - Die Nahrungsaufnahme wird nicht nur durch den Bedarf an Energie, sondern auch durch den Bedarf an essenziellen Nährstoffen wie z. B. Protein bestimmt. Es war zwar bekannt, wie proteinreiche Nahrung eine Sättigung vermittelt, jedoch war unklar, wie eine proteinarme Ernährung den Appetit anregt. Ziel dieser Arbeit ist es daher, zu untersuchen, wie Nahrung mit einem niedrigen Proteingehalt detektiert wird und die Anpassung des Organismus im Hinblick auf den Metabolismus und das Ernährungsverhalten erfolgt. Diese Arbeit liefert klare Beweise dafür, dass das aus der Leber stammende Hormon Fibroblast growth factor 21 (FGF21) ein endokrines Signal einer Nahrungsproteinrestriktion ist, wobei der zelluläre Aminosäuresensor general control nonderepressible 2 kinase (GCN2) als Regulator von FGF21 während der Proteinrestriktion fungiert. Im Gehirn vermittelt FGF21 die durch Proteinrestriktion induzierten Stoffwechselreaktionen, z.B. den Anstieg des Energieverbrauches, die Erhöhung der Nahrungsaufnahme und eine Verbesserung der Insulinsensitivität sowie der Glukosehomöostase. Darüber hinaus schützt das durch eine protein- oder methioninarme Diät induzierte FGF21 New Zealand Obese (NZO)-Mäuse, einem Tiermodell für den humanen Typ-2-Diabetes, vor einer Diabetesentstehung. FGF21 spielt bei Nagetieren und Menschen eine wichtige Rolle hinsichtlich der Detektion einer diätetischen Proteinrestriktion sowie eines Ungleichgewichtes der Makronährstoffe zueinander und vermittelt die adaptiven Verhaltens- und Stoffwechselreaktionen. Dies macht FGF21 zu einem kritischen physiologischen Signal der Nahrungsproteinrestriktion und unterstreicht den wichtigen, aber oft übersehenen Einfluss der Nahrungsproteine auf den Stoffwechsel und das Nahrungsaufnahmeverhalten, unabhängig vom Energiegehalt der Nahrung. KW - protein restriction KW - autophagy KW - thermogenesis KW - appetite KW - hyperglycemia KW - methionine restriction KW - bone KW - FGF21 KW - energy expenditure KW - GCN2 KW - metabolism KW - food choice KW - type 2 diabetes Y1 - 2021 ER -